King Fahad Specialist Hospital-Dammam is a hospital in the Eastern region of Saudi Arabia.

During the past decade, King Fahad Specialist Hospital conducted 15 clinical trials. In the 10-year time frame, 15 clinical trials started and 2 clinical trials were completed, i.e. on average, 13.3% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 2 clinical trials were completed. i.e. 28.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "King Fahad Specialist Hospital" #1 sponsor was "Celgene" with 3 trials, followed by "King Fahad Specialist Hospital Dammam" with 3 trials sponsored, "Biogen" with 2 trials sponsored, "Eli Lilly and Company" with 2 trials sponsored and "Janssen Research & Development, LLC" with 2 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "King Fahad Specialist Hospital" #1 collaborator was "Australasian Society for Infectious Diseases" with 1 trials as a collaborator, "Australian Society for Antimicrobials" with 1 trials as a collaborator, "International Society of Chemotherapy" with 1 trials as a collaborator, "John Hopkins Aramco Healthcare" with 1 trials as a collaborator and "King Abdulaziz Medical City" with 1 trials as a collaborator. Other collaborators include 7 different institutions and companies that were collaborators in the rest 17 trials.

According to Clinical.Site data, the most researched conditions in "King Fahad Specialist Hospital" are "Crohn Disease" (3 trials), "Muscular Atrophy, Spinal" (2 trials), "Airway Complication of Anesthesia" (1 trials), "Bacteremia Caused by Gram-Negative Bacteria" (1 trials) and "Bloodstream Infections" (1 trials). Many other conditions were trialed in "King Fahad Specialist Hospital" in a lesser frequency.

Most popular intervention types in "King Fahad Specialist Hospital" are "Drug" (13 trials), "Other" (4 trials) and "Diagnostic Test" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "Ozanimod" (3 trials), "Guselkumab" (2 trials), "Meropenem" (2 trials) and "Nusinersen" (2 trials). Other intervention names were less common.

The vast majority of trials in "King Fahad Specialist Hospital" are 16 trials for "All" genders.

Currently, there are NaN active trials in "King Fahad Specialist Hospital". undefined are not yet recruiting, 6 are recruiting, 2 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 1 completed trials in King Fahad Specialist Hospital, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in King Fahad Specialist Hospital, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 2 trials that are defined as “Not Applicable".